Authors: Jade Parker, Editor
The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor Lynparza® (olaparib) to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.
The decision makes olaparib the first and only approval for a PARP inhibitor for use beyond ovarian cancer. It is the first time any drug has been approved specifically to treat BRCA-mutated breast cancer.
The approval is a result of the highly promising results published from the